PharmExec Picks:
Having trouble viewing this e-mail? Click here.
feed back

Update My Profile | Advertise With Us | Visit PharmExec.com |
PRINT SUBSCRIBE | DIGITAL SUBSCRIBE


Pharm Exec Picks is a biweekly eletter that delivers the most popular news and articles from the pharma space and highlights what's trending on social media.


Top 5 Stories :
States Face Harsh Realities of Obamacare
For the 17 states that set up their own state exchanges under Obamacare, finding ways to manage a couple aspects of the new law are turning 2015 into a “Year of Harsh Realities.” Tom Norton explains why.
Read more
Hard Science, High Hopes: Dealmakers' Roundtable
The momentum behind dealmaking in pharma and biotech is so undeniable that a popular query has been to try to get someone to take the dark side, contrarian position, to hint at a disturbance in a growing bubble.
Read more
Embedding Market Access in Today's Pharma Business Model
As private and government payers around the world grow more powerful, obtaining market access promptly, at an appropriate price, has become critical to company success.
Read more
Marketing: Medical Devices vs. Pharma
If you've spent any time working in the device industry, you've probably heard pharma marketers make premature assumptions about what it takes to market a medical device.
Read more
Deep Breadth: GSK Doubles Down on COPD and Asthma
Despite a patent expiry in 2010, generic versions of Advair aren't expected to appear on the market for two more years. It took FDA eight years to develop a blueprint for how generics manufacturers might establish an acceptable bioequivalence for Advair, GSK's blockbuster fluticasone propionate/salmeterol xinafoate combo inhaler.
Read more
Trending on Social Media :
Q&A: The Future of Clinical Trial Data Sharing
 The push to increase transparency of clinical trial data continues to build considerable momentum, amid such factors as the explosion of digital health and new requirements by regulators in the U.S. and Europe to disclose study results to the public
Read more
Turkey Sees Growth in Pharma Market
According to a report unveiled at week's CPhI Istanbul, the pharmaceutical industry in Turkey increased by 8.8% in 2014 on the previous year, with growth in the coming years expected to come mostly from generic drugs.
Read more
Generics Industry Calls for Changes to GDUFA
 Prominent generic drug industry groups have called for major changes to the Generic Drug User Fee Act (GDUFA), reports Alexander Gaffney of raps.org this week.
Read more
Follow Us